[Cutaneous side effects induced by D-penicillamine in the treatment of rheumatoid arthritis].
After considering the cutaneous side effects of D-penicillamine in rheumatoid arthritis management, a few cases of cutaneous adverse reaction observed in 5 (13%) of 38 patients, who received the drugs, are described. Two patients had an early rash; one showed a late rash; one had a late rash with symptoms of initial pemphigus and drug-induced LES (presence of antinuclear and anti-dsDNA antibodies). Finally, one patient showed a drug-induced pemphigus with high titre of reticular anti-skin antibodies. All these manifestations required definitive discontinuance of the drug.
Broggini
M
M
U.S.S.L. n. 3, Ospedale F. del Ponte, Varese.
Baratelli
E
E
Cappelli
A
A
Crespi
E
E
Filardi
P G
PG
Volontè
S
S
D000906:Antibodies / Q000032:analysis; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D002467:Cell Nucleus / Q000276:immunology; D004247:DNA / Q000276:immunology; D003875:Drug Eruptions / Q000209:etiology / Q000276:immunology; D005260:Female; D006801:Humans; D008875:Middle Aged; D010392:Pemphigus / Q000139:chemically induced / Q000276:immunology; D010396:Penicillamine / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects* / Q000276:immunology; D013997:Time Factors
D000906:Antibodies; D004247:DNA; D010396:Penicillamine
Gli effetti collaterali cutanei indotti dalla D-penicillamina nel trattamento della artrite reumatoide.